达格列净联合门冬胰岛素30对2型糖尿病患者的应用效果

Application Effect of Dapagliflozin Combined with Insulin Aspart 30 in Patients with Type 2 Diabetes Mellitus

目的 探讨对2型糖尿病患者予达格列净联合门冬胰岛素30治疗的临床效果。方法 选择涟水县中医院2020年6月—2022年2月收治的90例2型糖尿病者为研究对象,以随机数表法分为二甲双胍联合门冬胰岛素30治疗的对照组(n=45)与达格列净联合门冬胰岛素治疗的观察组(n=45),对比两组治疗前后血糖、血脂指标、治疗前后血清超氧化物歧化酶(SOD)、丙二醛(MDA)水平。结果 观察组空腹血糖(6.97±0.40)mmol/L、餐后2 h血糖(8.52±0.75)mmol/L、糖化血红蛋白(7.36±0.48)%,均低于对照组(7.71±0.55)mmol/L、(9.65±0.84)mmol/L、(7.82±0.50)%,差异有统计学意义(t=7.299、6.731、4.452,P<0.05);观察组治疗后LDL-C为(1.75±0.80)mmol/L低于对照组(2.81±1.09)mmol/L,HDL-C为(1.80±0.33)mmol/L高于对照组(1.35±0.31)mmol/L,差异有统计学意义(t=5.259、6.667,P<0.05);观察组治疗后SOD为(77.45±6.23)nU/mL,高于对照组(71.73±6.08)nU/mL,MDA为(23.26±3.03)μmol/L,低于对照组(27.19±2.85)μmol/L,差异有统计学意义(t=4.408、6.338,P<0.05)。结论 对2型糖尿病者予以达格列净联合门冬胰岛素30治疗能有效改善患者血糖、血脂水平,并可减轻机体氧化应激损伤。

Objective To investigate the clinical effect of dapagliflozin combined with insulin aspart 30 in patients with type 2 diabetes mellitus.Methods A total of 90 patients with type 2 diabetes admitted to Lianshui County Hospital of Traditional Chinese Medicine from June 2020 to February 2022 were selected as the research subjects.The patients were divided into the control group(n=45)treated with metformin combined with insulin aspart 30 and the observation group treated with dapagliflozin combined with insulin aspart(n=45)by random number table method.The blood glucose indexes,blood lipid indexes,serum superoxide dismutase(SOD)and malondialdehyde(MDA)levels of the two groups before and after treatment were compared.Results The fasting blood glucose(6.97±0.40)mmol/L,2 h postprandial blood glucose(8.52±0.75)mmol/L,and glycosylated hemoglobin(7.36±0.48)%in the observation group were all lower than those in the control group(7.71±0.55)mmol/L,(9.65±0.84)mmol/L,(7.82±0.50)%,the difference was statistically significant(t=7.299,6.731,4.452,P<0.05).After treatment,the LDL-C of the observation group was(1.75±0.80)mmol/L,which was lower than that of the control group(2.81±1.09)mmol/L,and the HDL-C was(1.80±0.33)mmol/L,which was higher than that of the control group(1.35±0.31)mmol/L,the difference was statistically significant(t=5.259,6.667,P<0.05).After treatment,the SOD of the observation group was(77.45±6.23)nU/mL,which was higher than that of the control group(71.73±6.08)nU/mL,and the MDA was(23.26±3.03)μmol/L,which was lower than the control group(27.19±2.85)μmol/L,the difference was statistically significant(t=4.408,6.338,P<0.05).Conclusion The treatment of dapagliflozin combined with insulin aspart 30 in patients with type 2 diabetes can effectivelyimprove the blood glucose and blood lipid levels, and reduce the oxidative stress injury of the body.